Top 11 Small Cap Stocks to Buy with Biggest Upside Potential

Page 2 of 10

9. Janux Therapeutics, Inc. (NASDAQ:JANX)

Market Cap: $1.89 billion

Analyst Upside: 140.96%

Number of Hedge Fund Holders: 54

Janux Therapeutics, Inc. (NASDAQ:JANX) is a preclinical stage biopharmaceutical company that develops therapeutics based on the Tumor Activated T Cell Engager platform technology. The company ranks ninth on our list of the top small-cap stocks to invest in with the biggest upside potential and develops tumor-activated immunotherapies for cancer through two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).

On March 6, JonesTrading analyst Soumit Roy reiterated their bullish stance on Janux Therapeutics, Inc. (NASDAQ:JANX), giving it a Buy rating because of its upcoming catalysts and promising technological advancements. The company’s masking technology holds considerable potential, reporting best-in-class data amid a competitive environment. It is also anticipated to report updated data from its PSMA and EGFR targeting masked T cell engagers in 2025. The analyst expects this to further validate its technology, bolstering its clinical-stage programs.

Janux Therapeutics, Inc. (NASDAQ:JANX) also holds a considerable cash position of around $1.03 billion, which the analyst believes can support their present and future development and research initiatives. Another key factor behind Roy’s positive outlook is the company’s focus on transitioning to earlier treatment lines and exploring different dosing regimens. So, while the company is facing some competitive pressure, its long-term potential paints an optimistic picture.

Page 2 of 10